SEC Form 4 · accession 0001179022-19-000018
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joel Lewis
Director
Period of report
Jan 16, 2019
Accepted (ET)
Jan 18, 2019 · 5:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 16, 2019 | A | 11,653 | $4.72 | A | 63,133 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $4.72 | Jan 16, 2019 | A | 35,000 | A | — | Jan 16, 2029 | Common stock | 35,000 | 35,000 | D |
Explanation of responses
- F1These restricted shares were issued in lieu of cash retainer and meeting fees of $55,000 for 2019. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2019.
- F2The options vest 100% on January 16, 2020.